Suresh R Siddhanti

机构：BridgeBio (United States), Bridge Pharma (United States) · ORCID：0009-0008-3880-6209

发表论文 96 篇 · 总被引 6950 次 · h-index 27

代表论文

• Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (2025 · Journal of the American College of Cardiology · 被引 57)
• Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy (2024 · Circulation Heart Failure · 被引 21)
• Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM (2025 · Journal of the American College of Cardiology · 被引 12)
• Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-Up (2025 · Journal of Cardiac Failure · 被引 8)
• Increase in serum TTR levels observed with acoramidis treatment in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): insights from ATTRibute-CM and its open-label extension (2024 · European Heart Journal · 被引 4)
• IN PARTICIPANTS TREATED WITH ACORAMIDIS, ADDITION OF CONCOMITANT TAFAMIDIS DID NOT FURTHER INCREASE SERUM TTR LEVELS (2025 · Journal of the American College of Cardiology · 被引 3)